Your session is about to expire
← Back to Search
Checkpoint Inhibitor
Nivolumab-relatlimab Combo for Colorectal Cancer (RELATIVITY-123 Trial)
Phase 3
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histological confirmed previously treated colorectal cancer with adenocarcinoma histology with metastatic or recurrent unresectable disease at study entry
Must have sufficient tumor tissue & evaluable PD-L1 expression to meet the study requirements
Must not have
History of refractory hypertension not controlled with anti-hypertensive therapy, myocarditis (regardless of etiology), uncontrolled arrhythmias, acute coronary syndrome within 6 months prior to dosing, Class II congestive heart failure (as per the New York Heart Association Functional Classification), interstitial lung disease/pneumonitis or an active, known or suspected autoimmune disease
Confirmed tumor microsatellite instable high/deficient mismatch repair (MSI-H/dMMR) status as per local standard testing; MSI/MMR test results from initial diagnosis are acceptable
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to follow up visit 2 (approximately 135 days after last dose)
Awards & highlights
Summary
This trial is testing a combination of two drugs, relatlimab and nivolumab, for patients with a certain type of colorectal cancer who haven't responded to other treatments. The drugs help the immune system attack the cancer.
Who is the study for?
This trial is for adults with metastatic colorectal cancer that's not microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR). They must have tried 1-4 standard treatments including specific chemotherapy and targeted drugs, depending on their genetic makeup. People can't join if they've had certain heart issues, untreated brain metastases, prior immunotherapy or the study drugs Regorafenib/TAS-102.
What is being tested?
The study tests a fixed-dose combination of two immune checkpoint inhibitors, Nivolumab-relatlimab FDC (BMS-986213), against either Regorafenib or TAS-102 in patients who have previously treated metastatic colorectal cancer. It aims to see which treatment is more effective after other therapies have failed.
What are the potential side effects?
Nivolumab-relatlimab may cause immune-related side effects like inflammation in various organs, skin reactions, hormone gland problems (like thyroid dysfunction), and flu-like symptoms. Regorafenib and TAS-102 might cause fatigue, hand-foot syndrome, diarrhea, liver function changes among others.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My colorectal cancer, which cannot be surgically removed, has returned or spread.
Select...
My cancer has enough tissue for testing and shows PD-L1 activity.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have uncontrolled high blood pressure, recent heart issues, severe lung disease, or active autoimmune disease.
Select...
My tumor is confirmed to be MSI-H/dMMR.
Select...
I have previously been treated with immunotherapy, regorafenib, or TAS-102.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to follow up visit 2 (approximately 135 days after last dose)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to follow up visit 2 (approximately 135 days after last dose)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
TUDD-QoL: The time from randomization until definitive deterioration in the EORTC QLQ-C30 global health status/QoL scale score in randomized participants with PD-L1 CPS ≥ 1
Time Until Definitive Deterioration-Physical Function (TUDD-PF): The time from randomization until definitive deterioration in the EORTC QLQ-C30 physical function scale score in randomized participants with PD-L1 CPS ≥ 1
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm A: Nivolumab + Relatlimab Fixed-dose Combination (FDC)Experimental Treatment1 Intervention
Group II: Arm B: Investigator's ChoiceActive Control2 Interventions
Treatment with Regorafenib or TAS-102
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for colorectal cancer, particularly immune checkpoint inhibitors like Relatlimab and Nivolumab, work by targeting proteins that regulate the immune system's ability to attack cancer cells. Relatlimab inhibits LAG-3, a protein that suppresses T-cell activity, while Nivolumab blocks PD-1, another protein that downregulates immune responses.
By inhibiting these proteins, these drugs enhance the immune system's ability to recognize and destroy cancer cells, offering a promising treatment option for patients who have not responded to traditional therapies.
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.
Find a Location
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,679 Previous Clinical Trials
4,124,511 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have uncontrolled high blood pressure, recent heart issues, severe lung disease, or active autoimmune disease.My cancer worsened within 3 months after my last standard treatment.My colorectal cancer, which cannot be surgically removed, has returned or spread.I have had treatment for brain metastases and my neurological function is back to normal.I had severe side effects from previous chemotherapy despite support.My cancer has enough tissue for testing and shows PD-L1 activity.My tumor is confirmed to be MSI-H/dMMR.I have previously been treated with immunotherapy, regorafenib, or TAS-102.My cancer can be measured and has grown in an area previously treated with radiation.
Research Study Groups:
This trial has the following groups:- Group 1: Arm A: Nivolumab + Relatlimab Fixed-dose Combination (FDC)
- Group 2: Arm B: Investigator's Choice
Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger